← Eichor
Study identifier: NCT07503873 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)

Condition: Multiple Sclerosis  ·  Sponsor: TG Therapeutics, Inc.

PhasePhase 2
Planned participants350
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

The purpose of this study is to evaluate the PK and safety of ublituximab SC at different sites of administration and relative bioavailability of ublituximab SC administered with a prefilled pen versus syringe.

This description comes directly from the study's public registry record.

Talk to the study team

TG Therapeutics Clinical Support Team  ·  1-877-575-8489  ·  clinicalsupport@tgtxinc.com

Always discuss trial participation with your own doctor first.

Locations (39)

TG Therapeutics Investigational Trial SiteBihać, Bosnia and HerzegovinaRecruiting
TG Therapeutics Investigational Trial SiteSarajevo, Bosnia and HerzegovinaRecruiting
TG Therapeutics Investigational Trial SiteTuzla, Bosnia and HerzegovinaRecruiting
TG Therapeutics Investigational Trial SiteZenica, Bosnia and HerzegovinaRecruiting
TG Therapeutics Investigational Trial SiteTbilisi, GeorgiaRecruiting
TG Therapeutics Investigational Trial SiteTbilisi, GeorgiaRecruiting
TG Therapeutics Investigational Trial SiteTbilisi, GeorgiaRecruiting
TG Therapeutics Investigational Trial SiteTbilisi, GeorgiaRecruiting
TG Therapeutics Investigational Trial SiteShtip, North MacedoniaRecruiting
TG Therapeutics Investigational Trial SiteSkopje, North MacedoniaRecruiting
TG Therapeutics Investigational Trial SiteBydgoszcz, PolandRecruiting
TG Therapeutics Investigational Trial SiteKatowice, PolandRecruiting

+ 27 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07503873